27.04.2011 • News

J&J To Buy Synthes For $21.5 Billion

U.S. healthcare conglomerate Johnson & Johnson is expected to announce a $21.5 billion deal to buy Swiss medical device maker Synthes on Wednesday, the Wall Street Journal said, citing people familiar with the matter.

The deal is expected to value Synthes at 159 swiss francs ($180.51) a share, the Journal said, citing one person familiar with the matter.

Shares of Synthes closed at 146.50 Swiss francs on Tuesday.

Last week, Synthes confirmed it was in merger talks with J&J about a deal that would be J&J's largest-ever acquisition and reshape the medical devices industry.

The Journal said J&J is expected to pay one-third cash and the remainder in stock as part of the deal.

Synthes declined to comment on the Journal report to Reuters. J&J could not immediately be reached for comment.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.